Regencell Bioscience (NASDAQ:RGC) Trading Down 4.6% - What's Next?

Key Points

• Regencell Bioscience (RGC) fell 4.6% intraday to about $26.10 from a $27.37 close, with only 24,977 shares traded—roughly 94% below its average daily volume, indicating very thin liquidity.
• Analyst sentiment is negative with a consensus "Sell" rating and Weiss Ratings reaffirming a "sell (e+)" outlook.
• Institutional ownership is minimal at 0.13%, although several hedge funds have recently initiated or increased small positions; the stock sits below its 50‑day moving average ($27.81) but above its 200‑day moving average ($21.02).

Regencell Bioscience Holdings Limited (NASDAQ:RGC - Get Free Report)'s share price fell 4.6% during mid-day trading on Monday . The stock traded as low as $25.49 and last traded at $26.0990. 24,977 shares traded hands during trading, a decline of 94% from the average session volume of 441,729 shares. The stock had previously closed at $27.37.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Regencell Bioscience in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Regencell Bioscience currently has a consensus rating of "Sell".

Regencell Bioscience Stock Performance

The stock has a 50-day moving average price of $27.81 and a 200-day moving average price of $21.02.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Seven Fleet Capital Management LP acquired a new stake in shares of Regencell Bioscience during the 4th quarter worth approximately $92,000. Hudson Bay Capital Management LP acquired a new position in Regencell Bioscience during the 4th quarter valued at approximately $275,000. XTX Topco Ltd bought a new position in Regencell Bioscience during the 3rd quarter worth $598,000. Vident Advisory LLC grew its stake in Regencell Bioscience by 65.7% during the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company's stock worth $629,000 after buying an additional 11,866 shares during the last quarter. Finally, BNP Paribas Financial Markets acquired a new stake in Regencell Bioscience in the second quarter worth $768,000. 0.13% of the stock is owned by institutional investors and hedge funds.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.